237 related articles for article (PubMed ID: 24117542)
1. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
[TBL] [Abstract][Full Text] [Related]
2. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
Ponce D; Mendes M; Silva T; Oliveira R
Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
[TBL] [Abstract][Full Text] [Related]
3. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
[TBL] [Abstract][Full Text] [Related]
4. Alteplase for the treatment of catheter occlusion in pediatric patients.
Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
[TBL] [Abstract][Full Text] [Related]
5. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
6. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
Little MA; Walshe JJ
Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
[TBL] [Abstract][Full Text] [Related]
8. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
[TBL] [Abstract][Full Text] [Related]
9. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
10. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
Vercaigne LM; Zacharias J; Bernstein KN
Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
[TBL] [Abstract][Full Text] [Related]
11. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
12. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Gittins NS; Hunter-Blair YL; Matthews JN; Coulthard MG
Arch Dis Child; 2007 Jun; 92(6):499-501. PubMed ID: 17068072
[TBL] [Abstract][Full Text] [Related]
13. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
14. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Terrill KR; Lemons RS; Goldsby RE
J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
[TBL] [Abstract][Full Text] [Related]
15. Use of the femoral vein as insertion site for tunneled hemodialysis catheters.
Falk A
J Vasc Interv Radiol; 2007 Feb; 18(2):217-25. PubMed ID: 17327554
[TBL] [Abstract][Full Text] [Related]
16. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
18. Reteplase for dysfunctional hemodialysis catheter clearance.
Hilleman DE; Dunlay RW; Packard KA
Pharmacotherapy; 2003 Feb; 23(2):137-41. PubMed ID: 12587800
[TBL] [Abstract][Full Text] [Related]
19. Externalization of tunneled hemodialysis catheter in patients with tunnel or exit-site infections and limited access options.
Jaberi A; Hadziomerovic A; Toor SS; Galwa RP; Graham J; Thornhill RE; Ryan SE
J Vasc Interv Radiol; 2014 Apr; 25(4):561-6. PubMed ID: 24674214
[TBL] [Abstract][Full Text] [Related]
20. Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.
Wójtowicz D; Cholewa D; Faba AM; Domańska B; Kokoszka J; Kopacz K; Ficek R; Irzyniec T; Rotkegel SE; Chudek J
Ren Fail; 2018 Nov; 40(1):384-389. PubMed ID: 30010473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
